

1 **Title: Locus-specific stratification and prioritization unveil high risk genes**
2 **underlying hyperuricemia**

3 **Authors:** Jing Zhang^{1,2}, Yue Guo^{1,2}, Luyu Gong^{1,2}, Limei Xia^{1,2}, Qiaoqiao Liu^{1,2},
4 Kangchun Wang^{1,2}, Qi Wang^{1,2}, Zhaojun Liu^{1,2}, Zhaohui Qin³, Shaolin Shi^{4*}, Jingping
5 Yang^{1,2,4*}

6
7 ¹State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing
8 University, Nanjing, Jiangsu, 210093, China.

9 ²Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University,
10 Nanjing, Jiangsu, 210093, China.

11 ³Department of Biostatistics and Bioinformatics, Rollins School of Public Health,
12 Emory University, Atlanta, GA, 30322, USA.

13 ⁴National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated
14 Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, 210093, China.

15 * Corresponding author. Email: shaolinshi1001@yahoo.com; jpyang@nju.edu.cn.

16

17 **Abstract**

18 The development of alternative medications for urate-lowering therapies is imperative
19 for patients that are intolerant to current treatments. Despite GWAS have identified
20 hundreds of loci associated with serum urate levels, the mechanistic understanding and
21 discovery of drug targets remain difficult. This difficulty arises from the multiple-
22 independent-associations challenge in the genomic studies of complex diseases as
23 hyperuricemia. Here, we introduced a locus-specific stratification (LSS) and gene
24 regulatory prioritization score (GRPS) approach to address the multiple-independent-
25 associations challenge. By integrating with kidney single-cell chromatin accessibility
26 and gene expression, LSS identified functional SNPs, regulatory elements, and genes
27 for 118 loci. The interpretability was increased by 1.4 to 5.2 fold. GRPS prioritized
28 genes and nominated under-explored drug target with high confidence, which was
29 validated using CRISPR activation and phenotypic assays. Our findings not only
30 identified top causal genes but also proposed the regulatory mechanisms for pathogenic
31 genes, expanding our knowledge of the genetic contribution in complex diseases as
32 hyperuricemia.

33 **One-sentence summary**

34 A novel approach to comprehensively explore genetic contribution and nominate
35 reliable causal genes for complex diseases as hyperuricemia.

36

37 **Introduction**

38 Hyperuricemia, characterized by elevated serum urate levels, is a complex disease
39 affecting various complications (1-3). Although the dominant narrative about
40 hyperuricemia has focused on dietary, recent research suggests that diet plays only a
41 limited role in regulation of serum urate in the healthy population (4). Instead, it has
42 been estimated that genetic contribution for hyperuricemia ranges from 40% to 73%
43 (5). There are currently urate-lowering therapies developed based on genetic targets,
44 such as allopurinol, which inhibits xanthine oxidase and the production of urate, and
45 benzbromarone, which inhibits URAT1 and reabsorption of urate in kidney. However,
46 these medications caused hypersensitivity syndrome, hepatotoxicity or other adverse
47 effects in specific patient populations (6). Therefore, it is necessary to further nominate
48 disease-associated genes or drug targets in order to develop medications for intolerant
49 populations. Large-scale genome-wide association studies (GWAS) have identified
50 over 200 loci associated with serum urate levels (7, 8), but mechanistic understanding
51 of the causal variants and genes underlying these loci remains partially explored,
52 limiting the translation of genetic result to alternative medications.

53 For complex diseases, the presence of multiple independent associations at
54 disease-associated locus is commonly observed (9-12). For example, four regions at
55 *SLC2A9* locus have significant causal effects on serum urate levels (13). However, due
56 to limitation of computational burden, the most commonly used methods for identifying
57 causal variants, such as lead SNP extension by linkage disequilibrium (LD), genetic
58 and epigenetic fine mapping, or colocalization (14-17), assume exactly one causal
59 variant per locus (18, 19). As all the independent disease associations could contribute
60 to gene regulation and trait association at the locus, these above methods may not fully
61 map causal variants and leave a large number of loci mechanistically unresolved.
62 Recent studies have performed the colocalization analysis of urate-associated loci with
63 kidney expression quantitative trait loci (eQTLs), but the result could only characterize
64 risk for tens loci and did not find the well-known targets in kidney including *SLC22A12*

65 (encoding URAT1) and *SLC2A9* (encoding GLUT9) (7, 20). Therefore, it is urgent to
66 find an effective way to overcome the issue of multiple independent associations in
67 complex diseases and comprehensively understand the mechanism of genetic
68 contribution.

69 The multiple independent associations in complex diseases also accompany the
70 complexity of gene regulation at disease-associated locus, and hinder gene
71 prioritization. Previous studies have shown that drug targets with genetic supports are
72 more likely to be therapeutically valid (21, 22), but drug target discovery in complex
73 diseases remains challenging. The heritability of complex diseases could be explained
74 by the cumulative effects of many variants (23), which are mainly located in non-coding
75 regions and regulate gene expression in a cell-type-specific manner (24, 25). Thus,
76 cumulative-regulation-based methods to prioritize the candidate genes is expected to
77 nominate the most probable causal genes and potential drug targets. Recent regulation-
78 based methods have leveraged the causal gene nomination, but they are not developed
79 for complex diseases and have certain limitations. ABC-Max only assigned one variant-
80 gene pair with the strongest regulatory score (26), but overlooked the complex
81 regulation between variants and genes (24). Open Targets Genetics and H-MAGMA
82 took into account all the variant-gene connectivity, but the connectivity is considered
83 qualitatively rather than quantitatively (27, 28). The incompleteness of cumulative
84 regulation maps, together with incomplete variant coverage and the limited cell type
85 resolution, hinder the prioritization of causal genes. Thus, a method that systematically
86 and accurately considers the cumulative regulation is required for prioritizing genes for
87 complex disease.

88 In the current study, we propose a novel approach with locus-specific stratification
89 and prioritization to comprehensively explore genetic contribution in complex diseases
90 and nominate reliable disease-associated genes. Locus-specific stratification (LSS)
91 efficiently extract all high-risk variants in addition to lead SNP based on a locus-
92 specific background and overcome the challenge of multiple-independent-associations

93 in complex diseases. To prioritize genes, we develop gene regulatory prioritization
94 score (GRPS) to evaluate cumulative regulation on genes by integration high-risk
95 variants from LSS with scATAC-seq and scRNA-seq datasets. Using this strategy, we
96 efficiently resolved genetic risk mechanism for 118 out of 267 loci, and nominated
97 more reliable gene targets for hyperuricemia. We further validated the regulatory
98 potential of resolved high-risk variant on candidate causal gene by CRISPR activation
99 (CRISPRa), and evaluated the effect of top prioritized gene on cellular urate level. Our
100 study established a computational efficient method for GWAS interpretation of
101 complex disease, extended genetic mechanistic understanding of hyperuricemia, and
102 ultimately prioritizing genes with high confidence.

103 **Results**

104 **Locus-specific stratification leverages interpretability of loci with multiple-** 105 **independent-associations**

106 The GWAS of serum urate level exhibited overwhelming multiple-independent-
107 associations challenge. For the available GWAS results of serum urate level,
108 independent association analysis revealed 22 to 128 loci with multiple independent
109 associations, ranging from 69.95%-95.65% of all the loci (Fig. 1A). For instance, at
110 locus chr4:9,743,616-10,243,616 with lead SNP rs3775947, in addition to lead SNP
111 and SNPs within its high LD neighborhood, there were also numerous variants showing
112 extremely strong trait association with $-\log_{10}(\text{p-value})$ even over 1000 (Fig. 1B). This
113 suggested that such a locus may not be fully explained by only one association. Notably,
114 at such highly associated locus, the locus-specific background is much higher than
115 genome-wide background, suggesting a one-size-fits-all cutoff might not be appropriate.

116 We observed that the distribution of significance at locus with multiple-
117 associations tended to be reversed “L” shape with a plateau. The plateau was consisted
118 of numerous high-risk associations, and generally harbored the top quantile
119 associations (Fig. 1C and Fig. S1). In order to efficiently and comprehensively explore
120 the genetic contribution, we proposed the LSS strategy to extract all high-risk
121 associations based on locus-specific background. We ranked the variants by descending
122 significance of variant-trait associations within each locus and took the top quartile
123 associations as rank 1 for further analysis (Fig. 1D). LSS captured the multiple
124 independent associations (Fig. 1E and Fig. S1) without bringing in noise at locus with
125 single association (Fig. 1F and Fig. S2).

126 Previous studies highlighted that disease-associated variants enriched at tissue and
127 cell type specific regulatory regions (29-31). We thus identified the target tissue and
128 generated tissue specific single cell EpiMap to pinpoint the potential causal variants of

129 these high-risk associations. By LD regression, we found the regulatory contribution
130 from kidney tissue is highest (Fig. S3). We then focused on the regulatory mechanism
131 in kidney. We generated cell type EpiMap with our previously generated kidney
132 scATAC-seq data and integrated it with the rank 1 associations (Fig. 1D). The results
133 showed that our strategy could explain genomic function for 220 out of 267 loci from
134 the three studies (Table S1). When compared with other methods including high LD
135 extension, Bayesian fine-mapping and colocalization, we found LSS could improve the
136 interpretability of GWAS loci by 8.13% to 69.92% (Fig. 1G). Furthermore, we
137 examined the contribution of these functional high-risk variants, and found that the
138 variants identified by LSS contributed more highly and specifically to gout, the most
139 common complication of hyperuricemia (Fig. 1H). These results suggested that LSS
140 could pinpoint the functional high-risk variants for complex diseases more
141 comprehensively and specifically.

142 **LSS identified variants revealed cell-type-specific contribution on complex disease**

143 We further examined the cell types in which the identified high-risk variants could
144 play a role in. The result showed that 77.86% of these high-risk variants exhibited
145 chromatin accessibility in proximal tubular cells, and this fraction was followed by that
146 in distal tubular cell types (Fig. 2A). The result is consistent with fact that urate
147 homeostasis is maintained mainly through excretion by kidney tubules (20). We also
148 found that 48.12% of the variants located in regions only accessible in one cell type,
149 mostly in proximal tubular cells and then in distal tubules (Fig. 2B and Fig. S4). For
150 example, at the locus chr8:75,316,533-75,816,533 with lead SNP rs2941484, the lead
151 SNP and its proxy SNP by LD extension showed no accessibility in any kidney cell
152 type (Fig. 2C). We found by LSS that high-risk variant rs2943549, which is in an
153 independent association over 26kb away from the lead SNP, located in a region
154 specifically accessible in proximal tubular cell (Fig. 2C). The phenome-wide
155 association study (PheWAS) (32), which is a powerful approach to comprehensively

156 evaluate associations between genetic variants and phenotypes, revealed that rs2943549
157 has the strongest association with urate-related phenotypes among the traits (Fig. 2D).
158 In another locus chr4:9,743,616-10,243,616 with lead SNP rs3775947, a high-risk
159 variant rs4447862 in addition to lead SNP showed accessibility, revealing an additional
160 risk (Fig. 2E). Notably, rs4447862 demonstrated a remarkable association with uric
161 acid (Fig. 2F), yet this risk variant could not be identified by extension of the lead SNP.
162 These results suggested that high-risk variant from independent association could
163 function as genomic regulation in a cell-type-specific manner, and contribute
164 mechanistically to the genetic risk of hyperuricemia.

165 **Integrated regulatory network uncovers candidate causal genes of functional** 166 **high-risk variants**

167 Genetic lesions in non-coding regulatory elements contribute to disease by
168 modulating the causal gene expression (14). To fully explain the regulatory
169 mechanisms of the above functional high-risk variants, we integrated the scRNA-seq
170 and scATAC-seq profiles of kidney to construct the transcriptional regulatory networks
171 by identifying CREs with accessibility correlated to gene expression ('peak-to-gene
172 links') (Fig. 3A and Fig. S5A). Based on the regulatory network, we identified 160
173 protein-coding genes linked to 232 variants in 118 loci (Table S2). Our approach
174 interpreted mechanism for 1.4 to 5.2 fold more loci than the other approaches on the
175 same GWAS study (Fig. 3B), and identified an additional 32 to 85 candidate genes (Fig.
176 3C).

177 To examine the relevance of the identified candidate causal genes from functional
178 high-risk variants, we performed gene function analysis. The ontology and pathway
179 enrichment revealed that the genes were mainly involved in urate and organic anion
180 transport (Fig. S5B). Disease enrichment analysis showed that they were involved in
181 urate measurement and gout (Fig. 3D). Notably, genes linked with LSS-only high-risk
182 variants were also implicated in uric acid measurement (Fig. 3E and Fig. S5C). For

183 example, at the locus chr1:154,935,239-155,435,239, we found that independent high-
184 risk variant rs3814316, instead of lead SNP rs2070803, functioned as a regulatory
185 element in distal tubular cell types and linked to gene *MUC1* (Fig. 3F). *MUC1* has been
186 shown to be important for urate level as its mutation in tubulointerstitial nephropathy
187 patients can result in clinical manifestations of gout (33). In contrast, the lead SNP
188 rs2070803 showed no regulatory capacity for kidney *MUC1* expression. In consistent
189 with our finding, rs3814316 showed higher CADD score and cast even stronger eQTL
190 effect on *MUC1* than rs2070803 (Fig. 3G and 3H). These results suggested that the
191 independent high-risk variant rs3814316 identified by our study was more likely to be
192 the causal variant for disease association at the *MUC1* locus. Our findings have not only
193 identified candidate causal genes for disease-associated loci, but have also proposed the
194 more plausible regulatory mechanisms for pathogenic genes. Taken together, LSS is a
195 computational efficient method to deal with multiple-independent-association
196 challenge of complex disease, and could better explore the mechanism of complex
197 diseases.

198 **Comprehensive prioritization score nominates potential drug target genes**

199 As there are independent high-risk variants identified by LSS, there could be
200 complex regulation between variants and candidate causal genes. For urate-level
201 associated loci, we observed that 42% variants could be linked to more than one gene,
202 and 44% of the identified candidate causal genes could be regulated by more than one
203 variant (Fig. 4A and 4B). For example, *SLC22A12*, which encodes a known urate
204 transporter, URAT1, was regulated by up to 15 functional high-risk variants in 11
205 regulatory elements identified in this study at locus chr11: 64,315,390-64,815,390 with
206 lead SNP rs71456318 (Fig. S6). In order to nominate the most probable causal genes
207 for further targeted therapies, it is necessary to prioritize genes based on a
208 comprehensive regulation estimation. We developed gene regulatory prioritization
209 score (GRPS) to take full consideration of the complexity of transcriptional regulation.

210 GRPS did not require any previous functional evidence, but rather evaluated pathogenic
211 risk for genes objectively based on the risk level of causal variants linked to the gene,
212 the regulation strength of causal variants on the gene, and the polygenic effects of
213 multiple independent causal variants (Fig. 4C). Prioritizing all 160 candidate genes
214 using GRPS showed that the top candidates were overwhelmingly supported by
215 evidence for trait association from previous studies (Fig. 4D).

216 It is noteworthy that the top-ranking genes extensively enriched for known urate
217 transporters and gene targets that are already in clinical use or clinical trials (Fig. 4E).
218 *SLC22A11* and *SLC22A12* have been approved as confirmed drug targets for targeted
219 therapies of hyperuricemia and gout (34), and *SLC2A9* and *SLC17A1* have been
220 validated as potent targets for therapy in vivo (35, 36). Furthermore, the priority by
221 GRPS ranking could more thoroughly and effectively uncover putative drug targets
222 (Fig. 4F and 4G). For example, *SLC17A1* was ranked 5th in GRPS, but was positioned
223 at 42nd in Open Targets Genetics, and was even missed out in H-MAGMA or ABC-
224 Max (Table S3).

225 In addition to hyperuricemia, we also applied LSS and GRPS to other complex
226 diseases and traits including creatinine-based estimated glomerular filtration rate
227 (eGFR_{crea}), blood urea nitrogen (BUN), urinary albumin-to-creatinine ratio (UACR),
228 gout and chronic kidney disease (CKD). The results showed that LSS generally
229 increased the interpretability of GWAS for complex diseases and traits with multiple
230 independent associations (Fig. S7A-D), and GRPS uncovered candidate causal genes
231 with high credibility (Fig. S7E). All these results indicated that the approach was
232 generally applicable to GWAS of complex diseases and could leverage the investigation
233 of mechanism and drug target of complex diseases.

234 ***SLC17A4* as top nominator promoted the cellular urate transport**

235 Among the top nominated gene targets, *SLC17A4* was the one that has not been
236 demonstrated to be involved in urate levels (Fig. 4E). Although it was supposed that
237 *SLC17A4* encodes an organic anion transporter, its role in cellular urate transport and
238 regulatory mechanism have never been determined. At the GWAS locus
239 chr6:25,559,488-26,059,488 where *SLC17A4* located, the lead SNP rs1359232 did not
240 show regulatory potential, but the additional high-risk variant rs1165183 located at a
241 regulatory region and linked with the 81 kb upstream gene *SLC17A4* (Fig. 5A).
242 rs1165183-harboring-CRE was proximal tubular-specific accessible and *SLC17A4*
243 specifically expressed in proximal tubular cells (Fig. 5A and 5B). In order to verify the
244 regulatory potential of rs1165183-harboring-CRE on *SLC17A4*, we used CRISPRa
245 system (37) to activate the activity of the regulatory element (Fig. S8A). Upon
246 activation, we found that the expression of *SLC17A4* was significantly up-regulated
247 (Fig. 5C).

248 As rs1165183 was associated with urate level with $-\log_{10}(\text{p-value})$ as high as 148,
249 *SLC17A4* was a strong candidate gene to affect urate level. To further determine the
250 function of *SLC17A4* on urate level, we carried out functional experimental using a
251 sodium urate-induced model. We overexpressed *SLC17A4* in HEK293T cells which
252 did not express *SLC17A4* endogenously (Fig. 5D). We then added sodium urate and
253 monitored changes in urate levels. The results showed that overexpression of *SLC17A4*
254 significantly changed cellular urate levels upon sodium urate overload (Fig. 5E and Fig.
255 S8B). The results confirmed that rs1165183-element could modulate the expression of
256 *SLC17A4* which affected the transport of cellular urate.

257 **Discussion**

258 GWAS studies of serum urate levels have identified hundreds of genetic loci
259 associated with hyperuricemia. However, multiple independent association in complex
260 diseases complicates the deciphering of the mechanisms of these loci. Here, we
261 proposed an integrated strategy that combined LSS and GRPS to deal with the multiple

262 independent associations of complex diseases. LSS improved the functional
263 interpretability of GWAS for complex diseases. Based on the candidate causal variants
264 and genes revealed by LSS, GRPS considered the complexity of transcriptional
265 regulatory networks for gene prioritization, and comprehensively and accurately
266 nominated causal genes. Our work further investigated and confirmed the regulatory
267 mechanism and function of *SLC17A4* locus and contributed to a theoretical foundation
268 for the development of alternative medication in the future.

269 Our research has introduced a strategy for full understanding of genetic
270 contribution in complex diseases. LSS differs from previous approaches which assume
271 single association, it can efficiently and comprehensively extract high-risk variants
272 from all independent associations without increasing computational burden. It
273 significantly enhances the interpretability of GWAS results of complex diseases. For
274 example, LSS facilitates identification of the causal genes *SLC22A12* and *SLC22A11*.
275 In contrast, the previous colocalization analysis of serum urate GWAS and kidney
276 eQTL did not show the two genes as causal genes (7, 34). *SLC22A12* and *SLC22A11*
277 are in the locus which is highly associated with urate levels with $-\log_{10}(\text{p-value})$ as
278 high as 245. URAT1 encoded by *SLC22A12* is the target of benzbromarone which is an
279 well-known uricosuric drug that functions by increasing urate excretion in the kidney's
280 proximal tubule through inhibition of the dominant apical urate exchanger in the human
281 proximal tubule (38). OAT4 encoded by *SLC22A11* is the target of probenecid which
282 is approved to treat gout (34). All these evidences indicated *SLC22A12* and *SLC22A11*
283 are truly causal genes for genetic association of urate level. Additionally, our study
284 could reveal the regulatory mechanism for pathogenic genes. We identified the
285 potential causal variant rs38814316 instead of the lead SNP for the regulation of *MUC1*,
286 revealing an unknown regulatory mode for known pathogenic genes. Thus, LSS can be
287 used to leverage the interpretation of GWAS of complex diseases and fully uncover the
288 underlying mechanisms.

289 In evaluating the pathogenicity of all candidate causal genes, the GRPS considers
290 all essential factors for the regulatory prioritization. This strategy reliably identifies the
291 causal genes for complex diseases based on their fully linked genetic regulation,
292 without the necessity of prior functional evidence. This approach is valuable for
293 uncovering the genetic underpinnings of diseases, especially when experimental data
294 for biological function may be limited or unavailable. Compared to other methods such
295 as H-MAGMA, ABC-Max and Open Targets Genetics, which do not sufficiently
296 consider the complexity of regulation at loci in complex diseases, GRPS-prioritized top
297 genes exhibited a strong association with putative drug targets. We successfully
298 identified 4 drug targets in kidney in the top rank. In addition to already known drug
299 targets and our newly proposed drug target, it is interesting that *IGF1R* is among the
300 top prioritized genes. *IGF1R* have been already approved as drug targets for treating
301 other diseases (34). Our finding provides a favorable condition for drug repurposing.
302 Overall, it is indicated that comprehensive integration of regulatory information
303 provides a more reliable evaluation of gene pathogenicity, and can help identify
304 promising drug target genes to facilitate drug development for treating complex
305 diseases.

306 However, a potential limitation of this study is that it focused exclusively on
307 kidney tissue that shows the highest risk for hyperuricemia. In addition to kidney tissues,
308 we did not explore other tissues involved in urate metabolism, such as the intestine and
309 liver, which may also contribute to the pathogenesis of hyperuricemia (Fig. S3).
310 Subsequent applications of our proposed strategy in other tissues may expand the
311 understanding of the pathogenesis of hyperuricemia. Importantly, this work takes an
312 important step forward by providing comprehensive functional annotation of risk loci
313 in complex diseases. We have also tested our strategy to the GWAS of other kidney
314 complex diseases or traits and demonstrated the robust applicability of our strategy and
315 its power in tackling the complexities of genetic associations. With the ongoing
316 expansion of GWAS interpretation, the effective integration of LSS and GRPS will

317 offer further opportunities and possibilities for disease prediction, treatment and
318 prevention.

319

320 **References**

- 321 1. M. Dehlin, L. Jacobsson, E. Roddy, Global epidemiology of gout: prevalence,
322 incidence, treatment patterns and risk factors. *Nat Rev Rheumatol* **16**, 380-390
323 (2020).
- 324 2. C. Ponticelli, M. A. Podesta, G. Moroni, Hyperuricemia as a trigger of
325 immune response in hypertension and chronic kidney disease. *Kidney Int* **98**,
326 1149-1159 (2020).
- 327 3. X. Li *et al.*, Serum uric acid levels and multiple health outcomes: umbrella
328 review of evidence from observational studies, randomised controlled trials,
329 and Mendelian randomisation studies. *BMJ* **357**, j2376 (2017).
- 330 4. T. J. Major, R. K. Topless, N. Dalbeth, T. R. Merriman, Evaluation of the diet
331 wide contribution to serum urate levels: meta-analysis of population based
332 cohorts. *BMJ* **363**, k3951 (2018).
- 333 5. J. S. Park, Y. Kim, J. Kang, Genome-wide meta-analysis revealed several
334 genetic loci associated with serum uric acid levels in Korean population: an
335 analysis of Korea Biobank data. *J Hum Genet* **67**, 231-237 (2022).
- 336 6. N. Dalbeth, A. L. Gosling, A. Gaffo, A. Abhishek, Gout. *Lancet* **397**, 1843-
337 1855 (2021).
- 338 7. A. Tin *et al.*, Target genes, variants, tissues and transcriptional pathways
339 influencing human serum urate levels. *Nat Genet* **51**, 1459-+ (2019).
- 340 8. A. Kottgen *et al.*, Genome-wide association analyses identify 18 new loci
341 associated with serum urate concentrations. *Nat Genet* **45**, 145-154 (2013).
- 342 9. K. Watanabe, E. Taskesen, A. van Bochoven, D. Posthuma, Functional
343 mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**,
344 1826 (2017).
- 345 10. H. Lango Allen *et al.*, Hundreds of variants clustered in genomic loci and
346 biological pathways affect human height. *Nature* **467**, 832-838 (2010).
- 347 11. M. J. Flister *et al.*, Identifying multiple causative genes at a single GWAS
348 locus. *Genome Research* **23**, 1996-2002 (2013).
- 349 12. C. C. Chung *et al.*, Fine mapping of a region of chromosome 11q13 reveals
350 multiple independent loci associated with risk of prostate cancer. *Hum Mol*
351 *Genet* **20**, 2869-2878 (2011).
- 352 13. A. Tin *et al.*, Epigenome-wide association study of serum urate reveals
353 insights into urate co-regulation and the SLC2A9 locus. *Nature*
354 *Communications* **12**, (2021).

- 355 14. M. Song *et al.*, Mapping cis-regulatory chromatin contacts in neural cells links
356 neuropsychiatric disorder risk variants to target genes. *Nat Genet* **51**, 1252-
357 1262 (2019).
- 358 15. K. K. Farh *et al.*, Genetic and epigenetic fine mapping of causal autoimmune
359 disease variants. *Nature* **518**, 337-343 (2015).
- 360 16. G. Kichaev *et al.*, Integrating functional data to prioritize causal variants in
361 statistical fine-mapping studies. *PLoS Genet* **10**, e1004722 (2014).
- 362 17. C. Giambartolomei *et al.*, Bayesian Test for Colocalisation between Pairs of
363 Genetic Association Studies Using Summary Statistics. *Plos Genetics* **10**,
364 (2014).
- 365 18. J. C. Ulirsch *et al.*, Interrogation of human hematopoiesis at single-cell and
366 single-variant resolution. *Nat Genet* **51**, 683-+ (2019).
- 367 19. K. J. Gaulton, S. Preissl, B. Ren, Interpreting non-coding disease-associated
368 human variants using single-cell epigenomics. *Nat Rev Genet* **24**, 516-534
369 (2023).
- 370 20. N. Dalbeth *et al.*, Gout. *Nat Rev Dis Primers* **5**, 69 (2019).
- 371 21. E. A. King, J. W. Davis, J. F. Degner, Are drug targets with genetic support
372 twice as likely to be approved? Revised estimates of the impact of genetic
373 support for drug mechanisms on the probability of drug approval. *Plos Genet*
374 **15**, (2019).
- 375 22. M. R. Nelson *et al.*, The support of human genetic evidence for approved drug
376 indications. *Nat Genet* **47**, 856-860 (2015).
- 377 23. A. K. Wong, R. S. G. Sealfon, C. L. Theesfeld, O. G. Troyanskaya, Decoding
378 disease: from genomes to networks to phenotypes. *Nat Rev Genet* **22**, 774-790
379 (2021).
- 380 24. J. A. Morris *et al.*, Discovery of target genes and pathways at GWAS loci by
381 pooled single-cell CRISPR screens. *Science* **380**, 705-+ (2023).
- 382 25. V. Tam *et al.*, Benefits and limitations of genome-wide association studies.
383 *Nat Rev Genet* **20**, 467-484 (2019).
- 384 26. J. Nasser *et al.*, Genome-wide enhancer maps link risk variants to disease
385 genes. *Nature* **593**, 238-243 (2021).
- 386 27. E. Mountjoy *et al.*, An open approach to systematically prioritize causal
387 variants and genes at all published human GWAS trait-associated loci. *Nat*
388 *Genet* **53**, 1527-+ (2021).
- 389 28. N. Y. A. Sey *et al.*, A computational tool (H-MAGMA) for improved
390 prediction of brain-disorder risk genes by incorporating brain chromatin
391 interaction profiles. *Nat Neurosci* **23**, 583-593 (2020).
- 392 29. P. W. Hook, A. S. McCallion, Leveraging mouse chromatin data for
393 heritability enrichment informs common disease architecture and reveals
394 cortical layer contributions to schizophrenia. *Genome Res* **30**, 528-539 (2020).
- 395 30. K. Zhang *et al.*, A single-cell atlas of chromatin accessibility in the human
396 genome. *Cell* **184**, 5985-6001 e5919 (2021).

- 397 31. C. A. Boix, B. T. James, Y. P. Park, W. Meuleman, M. Kellis, Regulatory
398 genomic circuitry of human disease loci by integrative epigenomics. *Nature*
399 **590**, 300-307 (2021).
- 400 32. D. Diogo *et al.*, Phenome-wide association studies across large population
401 cohorts support drug target validation. *Nat Commun* **9**, 4285 (2018).
- 402 33. G. H. Kim, J. B. Jun, Altered Serum Uric Acid Levels in Kidney Disorders.
403 *Life (Basel)* **12**, (2022).
- 404 34. K. Trajanoska *et al.*, From target discovery to clinical drug development with
405 human genetics. *Nature* **620**, 737-745 (2023).
- 406 35. Z. A. Zhao *et al.*, CDER167, a dual inhibitor of URAT1 and GLUT9, is a
407 novel and potent uricosuric candidate for the treatment of hyperuricemia (vol
408 43, pg 121, 2022). *Acta Pharmacol Sin* **43**, 1884-1884 (2022).
- 409 36. R. Bao *et al.*, Eurycomanol alleviates hyperuricemia by promoting uric acid
410 excretion and reducing purine synthesis. *Phytomedicine* **96**, 153850 (2022).
- 411 37. S. Konermann *et al.*, Genome-scale transcriptional activation by an engineered
412 CRISPR-Cas9 complex. *Nature* **517**, 583-588 (2015).
- 413 38. V. F. Azevedo, I. A. Kos, A. B. Vargas-Santos, G. da Rocha Castelar Pinheiro,
414 E. dos Santos Paiva, Benzbromarone in the treatment of gout. *Advances in*
415 *Rheumatology* **59**, 37 (2019).
- 416 39. Q. Wang *et al.*, Single-cell chromatin accessibility landscape in kidney
417 identifies additional cell-of-origin in heterogenous papillary renal cell
418 carcinoma. *Nat Commun* **13**, 31 (2022).
- 419 40. P. C. Wilson *et al.*, The single-cell transcriptomic landscape of early human
420 diabetic nephropathy. *Proc Natl Acad Sci U S A* **116**, 19619-19625 (2019).

421

422 **Acknowledgments**


423 **Funding:** J.Y. is grateful to support from The Open Project of Jiangsu Provincial
424 Science and Technology Resources (Clinical Resources) Coordination Service
425 Platform JSRB2021-01. S. S. is grateful to support from National Natural Science
426 Foundation of China (82170723).

427 **Author Contributions:** J.Y. conceived of and designed the project. J.Z., Y.G., and L.G.
428 performed research. J.Z., L.X., Q.L., K.W., and Q.W. contributed to data analysis. J.Y.,
429 J.Z., S.S., and Z.Q. wrote the manuscript with input from all authors. All authors read
430 and approved the final submission of the manuscript.

431 **Conflict of interests:** The authors declare that they have no competing interests.

432 **Data and materials availability:** The kidney scATAC-seq publicly available data used
433 in this study are available in the Gene Expression Omnibus (GEO) under GSE166547
434 (39). The kidney scRNA-seq data used in this study are publicly available in the GEO
435 under GSE131882 (40). Kidney tubule eQTL derives from NephQTL browser
436 (<https://www.nephqtl.org>). Epigenomic profiles from EpiMap is available at
437 <http://compbio.mit.edu/epimap/>. Main code used in processing and analysis of the
438 data in this article is available at <https://github.com/NJU-labyang/hyperuricemia>. Any
439 code not provided there will be made available upon request.

440




441

442 **Fig. 1 Locus-specific stratification leverages interpretability of loci with multiple-**

443 **independent-associations. (A) Number of loci with single or multiple independent**

444 associations in three serum urate GWAS studies, respectively. **(B and C)** LocusZoom
445 plot **(B)** and quantile-quantile plot **(C)** for GWAS result at locus chr4:9,743,616-
446 10,243,616 with lead SNP rs3775947. **(D)** Overview of the LSS strategy. The variants
447 were ranked by descending significance of variant-trait associations within each locus,
448 and candidate high-risk variants defined as those in the top quartile. High-risk variants
449 were further integrated with kidney scATAC-seq data to identify functional high-risk
450 variants. **(E and F)** Quantile-quantile plots for GWAS result at locus with multiple
451 independent associations **(E)** or single association **(F)**. The lead SNP and independent
452 ($LD R^2 < 0.8$) high-risk (Rank1) SNPs were highlighted. **(G)** Percentage of interpretable
453 loci for GWAS of serum urate (EA Tin). Four strategies including LSS, LD extension
454 of lead SNP, Bayesian fine-mapping and kidney colocalization were used. **(H)** Odds
455 ratios of genetic contribution for functional high-risk variants identified by four
456 strategies. eGFR_{crea}, creatinine-based estimated glomerular filtration rate; BUN, blood
457 urea nitrogen; CKD, chronic kidney disease; LM, leptin measurement; CD, Crohn's
458 disease; MS, multiple sclerosis.




459

460 **Fig. 2 LSS reveals cell-type-dependent functional variants of hyperuricemia.** (A)
 461 Number of high-risk variants overlapping with regulatory elements in each cell type of
 462 the kidney, including proximal convoluted tubule (PCT), collecting duct alpha
 463 intercalated cells (CDICA), distal convoluted tubule (DCT), collecting duct principal
 464 cell (CDPC), loop of Henle (LOH), endothelium (ENDO), podocyte (PODO), parietal
 465 epithelial cells (PEC), and mesangial cell (MES). (B) Proportion of functional high-risk

466 variants that exert their function in unique cell types, 2-3 cell types, and multiple cell
467 types in kidney. **(C)** LocusZoom plot of GWAS result in locus chr8:75,316,533-
468 75,816,533 with lead SNP rs2941484 (top) and genome browser view for the
469 highlighted region (bottom). The genome browser tracks include chromatin
470 accessibilities in cell types from kidney scATAC-seq, the position of the lead SNP,
471 proxy SNP (LD extension of lead SNP) and functional high-risk SNP. **(D)** The
472 PheWAS results for rs2943549 with colors representing significantly associated
473 diseases and traits ($p < 0.05$). **(E)** LocusZoom plot and genome browser view for locus
474 chr4:9,743,616-10,243,616 with lead SNP rs3775947 as **(C)**. **(F)** The PheWAS results
475 for rs4447862 as **(D)**.

476




477

478 **Fig. 3 Regulatory network elucidates the regulatory mechanism for target genes**
 479 **and functional variants in hyperuricemia.** (A) Overview of the construction of
 480 transcriptional regulatory networks of kidney cell types by computing the correlation
 481 between chromatin accessibility and gene expression. (B) Percentage of loci with

482 kidney candidate causal genes identified in GWAS of serum urate (EA Tin). (C)
483 Number of candidate causal genes identified by different strategies. (D and E) Top 5
484 diseases enriched for the candidate causal genes identified with all LSS high-risk
485 variants (D) or LSS-only high-risk variants (E). (F) LocusZoom plot of GWAS result
486 in locus chr1:154,935,239-155,435,239 with the lead SNP rs2070803 (top), and
487 genome browser view of the highlighted region (bottom). The genome browser includes
488 overlaid track of chromatin accessibilities in kidney cell types, the tracks for chromatin
489 accessibilities in DCT or CDPC, the tracks for location of the lead SNP, proxy SNP and
490 functional high-risk SNP, the track for gene location, and the track for the peak-to-gene
491 linkage. rs3814316-harboring-CRE and *MUC1* promoter are marked with orange and
492 yellow boxes, respectively. (G) CADD scores for lead SNP, proxy SNPs and functional
493 high-risk SNP. (H) Significance and effect size of the relationship between genotypes
494 of variants and *MUC1* expression in kidney tubule eQTL.

495




496

497 **Fig. 4 GRPS determines the priority of candidate risk genes.** (A) Percentage of
 498 functional high-risk variants that can regulate 1 or more genes. (B) Percentage of gene
 499 that can be regulated by 1 or more functional high-risk variants. (C) Overview of GRPS
 500 strategy. For each gene, a regulatory prioritization score is calculated based on
 501 cumulative regulations (Methods). (D) Percentage of genes supported by prior evidence.
 502 Genes are divided into 4 groups based on GRPS from highest to lowest. (E) Top 25%
 503 genes ranked by the GRPS prioritization with their annotation as putative drug targets,

504 urate transporter, and disease association by DISEASE displayed. (F and G) The
505 performance of four different prioritizing methods in predicting the probability (F) and
506 odds ratio (G) of putative drug targets, which was evaluated by logistic regression.

507



508

509 **Fig. 5 *SLC17A4* is regulated by high-risk variant and promotes the transport of**
 510 **uric acid.** (A) LocusZoom plot of GWAS result in locus chr6:25,559,488-26,059,488
 511 with lead SNP rs1359232 (top), and genome browser view of the highlighted region
 512 (bottom). The genome browser includes tracks for chromatin accessibilities in kidney

513 cell types, the position of the lead SNP and functional high-risk SNP, the location of
514 sgRNA designed for CRISPRa experiment, the location of genes, and the peak-to-gene
515 linkage. rs1165183-harboring-CRE and *SLC17A4* promoter are marked with orange
516 and yellow boxes, respectively. **(B)** Gene expression of *SLC17A4* in kidney cell types.
517 **(C)** *SLC17A4* expression determined by qPCR in CRISPRa HEK293T lines treated
518 with non-targeting negative sgRNA or rs1165183-harboring-CRE sgRNA (CRE
519 sgRNA) (n=3, two-tailed Student's t test, P-value for cells treated with negative sgRNA
520 vs CRE sgRNA is 0.005, * indicates P-value <0.05). **(D)** *SLC17A4* expression in
521 HEK293T cells treated with negative control plasmid and *SLC17A4* overexpression
522 (OE) plasmid (n=3, two-tailed Student's t test, P-value for cells treated with negative
523 control plasmid vs *SLC17A4* OE plasmid is 0.0006, * indicates P-value <0.05). **(E)**
524 Effects of *SLC17A4* overexpression (OE) on the intracellular urate levels of HEK293T
525 cells (n=3, two-tailed Student's t test, P-value for negative control cells which are
526 untreated or treated with uric acid (UA) is 0.0012; P-value for negative control vs
527 *SLC17A4* OE cells which are all treated with UA is 0.0033, P-value for negative control
528 cells vs *SLC17A4* OE cells which are all untreated with UA is 0.5185, P-value for
529 *SLC17A4* OE cells which are untreated or treated with UA is 0.0351; * indicates P-
530 value <0.05, NS indicates not significant).